*|MC:SUBJECT|*
up-to-date with a click!
Update April 2017
 
Curated by Peter Lansberg,
a Dutch lipidologist and educator, and
reviewed by prof. Philip Barter, Past President of the
International Atherosclerosis Society.

The IAS Statin Newsletter will keep you up-to-date with all recent statin publications, using a curated approach to select relevant articles.

Key publications

Other

  1. Okunrintemi V, Spatz ES, Di Capua P et al. Patient-Provider Communication and Health Outcomes Among Individuals With Atherosclerotic Cardiovascular Disease in the United States: Medical Expenditure Panel Survey 2010 to 2013. Circ Cardiovasc Qual Outcomes 2017; 10. http://www.ncbi.nlm.nih.gov/pubmed/?term=28373270

Add on treatments

  1. Bagdade J, Barter P, Quiroga C, Alaupovic P. Effects of Torcetrapib and Statin Treatment on ApoC-III and Apoprotein-Defined Lipoprotein Subclasses (from the ILLUMINATE Trial). Am J Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28431663
  2. Al Kindi M, Belanger AM, Sayegh K et al. Aortic Calcification Progression in Heterozygote Familial Hypercholesterolemia. Can J Cardiol 2017; 33:658-665. http://www.ncbi.nlm.nih.gov/pubmed/?term=28449836
  3. Knowles JW, Howard WB, Karayan L et al. Access to Non-Statin Lipid Lowering Therapies in Patients at High-Risk of Atherosclerotic Cardiovascular Disease. Circulation 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28446516
  4. Lunder M, Janic M, Savic V et al. Very low-dose fluvastatin-valsartan combination decreases parameters of inflammation and oxidative stress in patients with type 1 diabetes mellitus. Diabetes Res Clin Pract 2017; 127:181-186. http://www.ncbi.nlm.nih.gov/pubmed/?term=28384560
  5. Hagiwara N, Kawada-Watanabe E, Koyanagi R et al. Low-density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ-PROPER study, a prospective, open-label, randomized trial. Eur Heart J 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28430910
  6. Lafeber M, Spiering W, Visseren FL et al. Impact of switching from different treatment regimens to a fixed-dose combination pill (polypill) in patients with cardiovascular disease or similarly high risk. Eur J Prev Cardiol 2017:2047487317695616. http://www.ncbi.nlm.nih.gov/pubmed/?term=28436727
  7. Shinnakasu A, Yamamoto K, Kurano M et al. The Combination Therapy of Fenofibrate and Ezetimibe Improved Lipid Profile and Vascular Function Compared with Statins in Patients with Type 2 Diabetes. J Atheroscler Thromb 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28450679
  8. Davies GM, Vyas A, Baxter CA. Economic evaluation of ezetimibe treatment in combination with statin therapy in the United States. Journal of medical economics 2017:1-20. http://www.ncbi.nlm.nih.gov/pubmed/?term=28426345
  9. Nakagawa I, Park HS, Yokoyama S et al. Pretreatment with and ongoing use of omega-3 fatty acid ethyl esters reduce the slow-flow phenomenon and prevent in-stent restenosis in patients undergoing carotid artery stenting. Journal of vascular surgery 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28359716
  10. Sana T, Aslam B, Aslam N et al. Therapeutic effect of atorvastatin on kidney functions and urinary excretion of Glimepiride in healthy adult human male subjects. Pak J Pharm Sci 2016; 29:2321-2326. http://www.ncbi.nlm.nih.gov/pubmed/?term=28375090
  11. Catapano AL, Lee LV, Louie MJ et al. Efficacy of alirocumab according to background statin type and dose: pooled analysis of 8 ODYSSEY Phase 3 clinical trials. Scientific reports 2017; 7:45788. http://www.ncbi.nlm.nih.gov/pubmed/?term=28374849

Atorvastatin/Rosuvastatin

  1. Mansour H, Ghaleb R. Atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery. Atherosclerosis. Supplements 2017; 25:e2. http://www.ncbi.nlm.nih.gov/pubmed/?term=28452305
  2. Kanate AS, Hari PN, Pasquini MC et al. Recipient Immune-Modulation with Atorvastatin for Acute Graft-Versus-Host Disease Prophylaxis Following Allogeneic Transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28412518
  3. Zhao G, Wu L, Liu Y et al. Rosuvastatin reduces the recurrence rate following catheter ablation for atrial fibrillation in patients with heart failure. Biomedical reports 2017; 6:346-352. http://www.ncbi.nlm.nih.gov/pubmed/?term=28451398
  4. Yu Y, Zhu C, Liu C, Gao Y. Effect of Prior Atorvastatin Treatment on the Frequency of Hospital Acquired Pneumonia and Evolution of Biomarkers in Patients with Acute Ischemic Stroke: A Multicenter Prospective Study. BioMed research international 2017; 2017:5642704. http://www.ncbi.nlm.nih.gov/pubmed/?term=28357403
  5. Wiggers JK, van Golen RF, Verheij J et al. Atorvastatin does not protect against ischemia-reperfusion damage in cholestatic rat livers. BMC surgery 2017; 17:35. http://www.ncbi.nlm.nih.gov/pubmed/?term=28399849
  6. Reda A, Etman A, Abdel-Rahim A et al. Centralized Pan-Middle East Survey on the Under-Treatment of Hypercholesterolemia: Results from the CEPHEUS II Study in Egypt. Cardiology and therapy 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28357773
  7. Khera AV, Demler O, Adelman SJ et al. Cholesterol Efflux Capacity, HDL Particle Number, and Incident Cardiovascular Events. An Analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin). Circulation 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28450350
  8. Godino C, Pavon AG, Mangieri A et al. Platelet reactivity in response to loading dose of atorvastatin or rosuvastatin in patients with stable coronary disease before percutaneous coronary intervention: The STATIPLAT randomized study. Clin Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28422300
  9. de la Pena A, Cui X, Geiser J, Loghin C. No Dose Adjustment is Recommended for Digoxin, Warfarin, Atorvastatin or a Combination Oral Contraceptive When Coadministered with Dulaglutide. Clinical pharmacokinetics 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28357715
  10. Hausner H, Derving Karsbol J, Holst AG et al. Effect of Semaglutide on the Pharmacokinetics of Metformin, Warfarin, Atorvastatin and Digoxin in Healthy Subjects. Clinical pharmacokinetics 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28349387
  11. Woo HI, Kim SR, Huh W et al. Association of genetic variations with pharmacokinetics and lipid-lowering response to atorvastatin in healthy Korean subjects. Drug design, development and therapy 2017; 11:1135-1146. http://www.ncbi.nlm.nih.gov/pubmed/?term=28435225
  12. Maraqa AD. Effect of atorvastatin on interleukins and prostaglandin E2 in the kidney of type 1 diabetic rats. European cytokine network 2016; 27:97-101. http://www.ncbi.nlm.nih.gov/pubmed/?term=28396300
  13. Liang X, Yang LX, Guo R et al. Atorvastatin attenuates plaque vulnerability by downregulation of EMMPRIN expression via COX-2/PGE2 pathway. Experimental and therapeutic medicine 2017; 13:835-844. http://www.ncbi.nlm.nih.gov/pubmed/?term=28450907
  14. Zhu B, Gong Y, Yan G et al. Atorvastatin treatment modulates p16 promoter methylation to regulate p16 expression. The FEBS journal 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28425161
  15. Kebapcilar AG, Ilhan TT, Dursunoglu D et al. Efficacy comparison of oral rosuvastatin versus oral progesterone and bevacizumab on regression of surgically endometriotic implants in rats. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 2017:1-5. http://www.ncbi.nlm.nih.gov/pubmed/?term=28452240
  16. Hersi A, Giannoccaro JP, Howarth A et al. Statin Induced Regression of Cardiomyopathy Trial: A Randomized, Placebo-controlled Double-blind Trial. Heart views : the official journal of the Gulf Heart Association 2016; 17:129-135. http://www.ncbi.nlm.nih.gov/pubmed/?term=28400935
  17. Husain I, Akhtar M, Abdin MZ et al. Rosuvastatin ameliorates cognitive impairment in rats fed with high-salt and cholesterol diet via inhibiting acetylcholinesterase activity and amyloid beta peptide aggregation. Human & experimental toxicology 2017:960327117705431. http://www.ncbi.nlm.nih.gov/pubmed/?term=28441890
  18. Ribeiro NQ, Costa MC, Magalhaes TFF et al. Atorvastatin as a promising anticryptococcal agent. International journal of antimicrobial agents 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28450174
  19. Chee YR, Watson RW, McCarthy J et al. High dose statin prophylaxis in cardiopulmonary bypass related surgery: clinical utility. Journal of cardiothoracic surgery 2017; 12:20. http://www.ncbi.nlm.nih.gov/pubmed/?term=28359339
  20. Parida S, Swain TR, Routray SN, Maiti R. Effect of Atorvastatin on Glycaemic Parameters in Normoglycaemic and Prediabetic Subjects: A Prospective, Panel Study. J Clin Diagn Res 2017; 11:Fc04-fc09. http://www.ncbi.nlm.nih.gov/pubmed/?term=28384881
  21. Nixon DE, Bosch RJ, Chan ES et al. Effects of atorvastatin on biomarkers of immune activation, inflammation, and lipids in virologically suppressed, human immunodeficiency virus-1-infected individuals with low-density lipoprotein cholesterol <130 mg/dL (AIDS Clinical Trials Group Study A5275). J Clin Lipidol 2017; 11:61-69. http://www.ncbi.nlm.nih.gov/pubmed/?term=28391912
  22. Turner RM, Yin P, Hanson A et al. Investigating the prevalence, predictors, and prognosis of suboptimal statin use early after a non-ST elevation acute coronary syndrome. J Clin Lipidol 2017; 11:204-214. http://www.ncbi.nlm.nih.gov/pubmed/?term=28391887
  23. Mahmoud MO, Aboud HM, Hassan AH et al. Transdermal delivery of atorvastatin calcium from novel nanovesicular systems using polyethylene glycol fatty acid esters: Ameliorated effect without liver toxicity in poloxamer 407-induced hyperlipidemic rats. J Control Release 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28344015
  24. S SM, Kumari M, Pradeep AR et al. Comparative evaluation of efficacy of subgingivally delivered 1.2% Atorvastatin and 1.2% Simvastatin in the treatment of intrabony defects in chronic periodontitis: a randomized controlled trial. Journal of dental research, dental clinics, dental prospects 2017; 11:18-25. http://www.ncbi.nlm.nih.gov/pubmed/?term=28413591
  25. Oda T, Sawada Y, Yamaguchi T et al. Drug Eruption Caused by Rosuvastatin. J Investig Allergol Clin Immunol 2017; 27:140-141. http://www.ncbi.nlm.nih.gov/pubmed/?term=28398205
  26. Thongtang N, Diffenderfer MR, Ooi EM et al. Metabolism and proteomics of large and small dense LDL in combined hyperlipidemia. Effects of rosuvastatin. Journal of lipid research 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28392500
  27. Mirjanic-Azaric B, Jelic-Ivanovic Z, Zeljkovic A et al. The Pleiotropic Effects of Atorvastatin on Stable Angina Patients: Evidence by Analysis of High-Density Lipoprotein Size and Subclasses, and Plasma mRNA. Journal of medical biochemistry 2015; 34:314-322. http://www.ncbi.nlm.nih.gov/pubmed/?term=28356842
  28. Wu HF, Hristeva N, Chang J et al. Rosuvastatin Pharmacokinetics in Asian and White Subjects wild-type for Both OATP1B1 and BCRP Under Control and Inhibited Conditions. Journal of pharmaceutical sciences 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28385543
  29. Donzelli A, Schivalocchi A. Intensity of Statin Treatment and Mortality. JAMA cardiology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28445577
  30. Nunes JPL. Intensity of Statin Treatment and Mortality. JAMA cardiology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28445564
  31. Rodriguez F, Maron DJ, Heidenreich PA. Intensity of Statin Treatment and Mortality-Reply. JAMA cardiology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28445560
  32. Lee WS, Lee EG, Sung MS et al. Atorvastatin inhibits osteoclast differentiation by suppressing NF-kappaB and MAPK signaling during IL-1beta-induced osteoclastogenesis. The Korean journal of internal medicine 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28352062
  33. Bangalore S, Fayyad R, Laskey R et al. Body-Weight Fluctuations and Outcomes in Coronary Disease. N Engl J Med 2017; 376:1332-1340. http://www.ncbi.nlm.nih.gov/pubmed/?term=28379800
  34. Husain I, Akhtar M, Vohora D et al. Rosuvastatin Attenuates High-Salt and Cholesterol Diet Induced Neuroinflammation and Cognitive Impairment via Preventing Nuclear Factor KappaB Pathway. Neurochemical research 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28417263
  35. Rafeeq MM, Habib HS, Murad H et al. Effect of rosuvastatin on dyslipidemia and other parameters associated with metabolic syndrome in Saudi patients. Nigerian journal of clinical practice 2017; 20:445-453. http://www.ncbi.nlm.nih.gov/pubmed/?term=28406125
  36. Sana T, Aslam B, Aslam N et al. Therapeutic effect of atorvastatin on kidney functions and urinary excretion of Glimepiride in healthy adult human male subjects. Pak J Pharm Sci 2016; 29:2321-2326. http://www.ncbi.nlm.nih.gov/pubmed/?term=28375090
  37. Madonna R, Renna FV, Lanuti P et al. The acute impact of high-dose lipid-lowering treatment on endothelial progenitor cells in patients with coronary artery disease-The REMEDY-EPC early substudy. PLoS One 2017; 12:e0172800. http://www.ncbi.nlm.nih.gov/pubmed/?term=28394933
  38. Rockberg J, Jorgensen L, Taylor B et al. Risk of mortality and recurrent cardiovascular events in patients with acute coronary syndromes on high intensity statin treatment. Preventive medicine reports 2017; 6:203-209. http://www.ncbi.nlm.nih.gov/pubmed/?term=28373930
  39. Kilit C, Kocak FE, Pasali Kilit T. Comparison of the effects of high-dose atorvastatin and high-dose rosuvastatin on oxidative stress in patients with acute myocardial infarction: A pilot study. Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir 2017; 45:235-243. http://www.ncbi.nlm.nih.gov/pubmed/?term=28429691
  40. Dai J, Liu T, Wang K et al. [Effects of Atorvastatin on Proliferation and Apoptosis of Leukemia Cell Line HL-60 and Its Mechanism of Signal Pathway]. Zhongguo shi yan xue ye xue za zhi 2017; 25:403-407. http://www.ncbi.nlm.nih.gov/pubmed/?term=28446283

Cancer

  1. Liu B, Yi Z, Guan X et al. The relationship between statins and breast cancer prognosis varies by statin type and exposure time: a meta-analysis. Breast Cancer Res Treat 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28432513
  2. Yu EJ, Graber JM, Lu SE et al. Effect of Metformin and Statin Use on Survival in Pancreatic Cancer Patients: a Systematic Literature Review and Meta-analysis. Curr Med Chem 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28403788
  3. Xu B, Wang Q, Sung C. Telomerase Inhibitory Effects of Red Pigment Rubropunctatin and Statin Monacolin L Isolated from Red Yeast Rice. Genes 2017; 8. http://www.ncbi.nlm.nih.gov/pubmed/?term=28445391
  4. Epstein MM, Divine G, Chao CR et al. Statin use and risk of multiple myeloma: An analysis from the Cancer Research Network. International journal of cancer. Journal international du cancer 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28425616
  5. Verdoodt F, Kjaer Hansen M, Kjaer SK et al. Statin use and mortality among ovarian cancer patients: A population-based cohort study. International journal of cancer. Journal international du cancer 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28411390
  6. Berquist SW, Lee HJ, Hamilton Z et al. Statin utilization improves oncologic and survival outcomes in patients with dyslipidemia and surgically treated Renal Cell Carcinoma. Minerva urologica e nefrologica = The Italian journal of urology and nephrology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28376607
  7. Cheng Y, Luo R, Zheng H et al. Synergistic anti-tumor efficacy of sorafenib and fluvastatin in hepatocellular carcinoma. Oncotarget 2017; 8:23265-23276. http://www.ncbi.nlm.nih.gov/pubmed/?term=28423574
  8. Schnoeller TJ, Jentzmik F, Schrader AJ, Steinestel J. Influence of serum cholesterol level and statin treatment on prostate cancer aggressiveness. Oncotarget 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28445145
  9. Alizadeh J, Zeki AA, Mirzaei N et al. Mevalonate Cascade Inhibition by Simvastatin Induces the Intrinsic Apoptosis Pathway via Depletion of Isoprenoids in Tumor Cells. Scientific reports 2017; 7:44841. http://www.ncbi.nlm.nih.gov/pubmed/?term=28344327
  10. Dai J, Liu T, Wang K et al. [Effects of Atorvastatin on Proliferation and Apoptosis of Leukemia Cell Line HL-60 and Its Mechanism of Signal Pathway]. Zhongguo shi yan xue ye xue za zhi 2017; 25:403-407. http://www.ncbi.nlm.nih.gov/pubmed/?term=28446283

Children

  1. Johnson PK, Mendelson MM, Baker A et al. Statin-Associated Myopathy in a Pediatric Preventive Cardiology Practice. J Pediatr 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28365026

CVD

  1. Tan Q, Zhang S, Zou X et al. Fluvastatin therapy could not decrease progression of paroxysmal atrial fibrillation in non-valvular disease patients. Anatol J Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28430117
  2. Zhao G, Wu L, Liu Y et al. Rosuvastatin reduces the recurrence rate following catheter ablation for atrial fibrillation in patients with heart failure. Biomedical reports 2017; 6:346-352. http://www.ncbi.nlm.nih.gov/pubmed/?term=28451398
  3. de Lemos JA, Ayers CR, Levine BD et al. A Multimodality Strategy for Cardiovascular Risk Assessment: Performance in Two Population-Based Cohorts. Circulation 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28360032
  4. Ference BA, Ginsberg HN, Graham I et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28444290
  5. Guo R, Yang L, Mu L et al. Long-term statin use before primary percutaneous coronary intervention improves treatment outcomes of acute myocardial infarction. Experimental and therapeutic medicine 2017; 13:1578-1583. http://www.ncbi.nlm.nih.gov/pubmed/?term=28413512
  6. Hersi A, Giannoccaro JP, Howarth A et al. Statin Induced Regression of Cardiomyopathy Trial: A Randomized, Placebo-controlled Double-blind Trial. Heart views : the official journal of the Gulf Heart Association 2016; 17:129-135. http://www.ncbi.nlm.nih.gov/pubmed/?term=28400935
  7. Frohlich H, Raman N, Tager T et al. Statins attenuate but do not eliminate the reverse epidemiology of total serum cholesterol in patients with non-ischemic chronic heart failure. Int J Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28342630
  8. Bonsu KO, Owusu IK, Buabeng KO et al. Statin Treatment and Clinical Outcomes of Heart Failure Among Africans: An Inverse Probability Treatment Weighted Analysis. J Am Heart Assoc 2017; 6. http://www.ncbi.nlm.nih.gov/pubmed/?term=28365564
  9. Chee YR, Watson RW, McCarthy J et al. High dose statin prophylaxis in cardiopulmonary bypass related surgery: clinical utility. Journal of cardiothoracic surgery 2017; 12:20. http://www.ncbi.nlm.nih.gov/pubmed/?term=28359339
  10. Turner RM, Yin P, Hanson A et al. Investigating the prevalence, predictors, and prognosis of suboptimal statin use early after a non-ST elevation acute coronary syndrome. J Clin Lipidol 2017; 11:204-214. http://www.ncbi.nlm.nih.gov/pubmed/?term=28391887
  11. Nakagawa I, Park HS, Yokoyama S et al. Pretreatment with and ongoing use of omega-3 fatty acid ethyl esters reduce the slow-flow phenomenon and prevent in-stent restenosis in patients undergoing carotid artery stenting. Journal of vascular surgery 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28359716
  12. Donzelli A, Schivalocchi A. Intensity of Statin Treatment and Mortality. JAMA cardiology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28445577
  13. Nunes JPL. Intensity of Statin Treatment and Mortality. JAMA cardiology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28445564
  14. Rodriguez F, Maron DJ, Heidenreich PA. Intensity of Statin Treatment and Mortality-Reply. JAMA cardiology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28445560
  15. Rockberg J, Jorgensen L, Taylor B et al. Risk of mortality and recurrent cardiovascular events in patients with acute coronary syndromes on high intensity statin treatment. Preventive medicine reports 2017; 6:203-209. http://www.ncbi.nlm.nih.gov/pubmed/?term=28373930
  16. Liakopoulos OJ, Kuhn EW, Slottosch I et al. Statin Therapy in Patients Undergoing Coronary Artery Bypass Grafting for Acute Coronary Syndrome. The Thoracic and cardiovascular surgeon 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28427094

Endothelium/inflammation

  1. Umemoto T, Yasu T, Arao K et al. Pravastatin improves postprandial endothelial dysfunction and hemorheological deterioration in patients with effort angina pectoris. Heart Vessels 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28396938
  2. Nixon DE, Bosch RJ, Chan ES et al. Effects of atorvastatin on biomarkers of immune activation, inflammation, and lipids in virologically suppressed, human immunodeficiency virus-1-infected individuals with low-density lipoprotein cholesterol <130 mg/dL (AIDS Clinical Trials Group Study A5275). J Clin Lipidol 2017; 11:61-69. http://www.ncbi.nlm.nih.gov/pubmed/?term=28391912
  3. Yin M, Liu Q, Yu L et al. Downregulations of CD36 and Calpain-1, Inflammation, and Atherosclerosis by Simvastatin in Apolipoprotein E Knockout Mice. Journal of vascular research 2017; 54:123-130. http://www.ncbi.nlm.nih.gov/pubmed/?term=28448973
  4. Madonna R, Renna FV, Lanuti P et al. The acute impact of high-dose lipid-lowering treatment on endothelial progenitor cells in patients with coronary artery disease-The REMEDY-EPC early substudy. PLoS One 2017; 12:e0172800. http://www.ncbi.nlm.nih.gov/pubmed/?term=28394933

FH

  1. Al Kindi M, Belanger AM, Sayegh K et al. Aortic Calcification Progression in Heterozygote Familial Hypercholesterolemia. Can J Cardiol 2017; 33:658-665. http://www.ncbi.nlm.nih.gov/pubmed/?term=28449836
  2. Knowles JW, Howard WB, Karayan L et al. Access to Non-Statin Lipid Lowering Therapies in Patients at High-Risk of Atherosclerotic Cardiovascular Disease. Circulation 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28446516
  3. Rubba P, Gentile M, Marotta G et al. Causative mutations and premature cardiovascular disease in patients with heterozygous familial hypercholesterolaemia. Eur J Prev Cardiol 2017:2047487317702040. http://www.ncbi.nlm.nih.gov/pubmed/?term=28353356
  4. Bos S, Phillips M, Watts GF et al. Novel protein biomarkers associated with coronary artery disease in statin-treated patients with familial hypercholesterolemia. J Clin Lipidol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28434814
  5. Kastelein JJ, Hovingh GK, Langslet G et al. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial hypercholesterolemia. J Clin Lipidol 2017; 11:195-203.e194. http://www.ncbi.nlm.nih.gov/pubmed/?term=28391886

Genetics

  1. Xu Y, Wang Y, Zhi J et al. Impact of matrix metalloproteinase 9 rs3918242 genetic variant on lipid-lowering efficacy of simvastatin therapy in Chinese patients with coronary heart disease. BMC pharmacology & toxicology 2017; 18:28. http://www.ncbi.nlm.nih.gov/pubmed/?term=28390432
  2. Woo HI, Kim SR, Huh W et al. Association of genetic variations with pharmacokinetics and lipid-lowering response to atorvastatin in healthy Korean subjects. Drug design, development and therapy 2017; 11:1135-1146. http://www.ncbi.nlm.nih.gov/pubmed/?term=28435225
  3. Poinsot P, Collardeau Frachon S, Restier L et al. Childhood/adult-onset lysosomal acid lipase deficiency: A serious metabolic and vascular phenotype beyond liver disease-four new pediatric cases. J Clin Lipidol 2017; 11:167-177.e163. http://www.ncbi.nlm.nih.gov/pubmed/?term=28391883
  4. Jiang F, Choi JY, Lee JH et al. The influences of SLCO1B1 and ABCB1 genotypes on the pharmacokinetics of simvastatin, in relation to CYP3A4 inhibition. Pharmacogenomics 2017; 18:459-469. http://www.ncbi.nlm.nih.gov/pubmed/?term=28350522

Guidelines

  1. Farnier M, Civeira F, Descamps O. How to implement clinical guidelines to optimise familial hypercholesterolaemia diagnosis and treatment. Atherosclerosis. Supplements 2017; 26:25-35. http://www.ncbi.nlm.nih.gov/pubmed/?term=28434482
  2. Reda A, Etman A, Abdel-Rahim A et al. Centralized Pan-Middle East Survey on the Under-Treatment of Hypercholesterolemia: Results from the CEPHEUS II Study in Egypt. Cardiology and therapy 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28357773
  3. Ascaso JF, Ferrari R. Practical recommendations for the management of cardiovascular risk associated with atherogenic dyslipidemia, with special attention to residual risk. Spanish adaptation of a European Consensus of Experts. Clin Investig Arterioscler 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28433209
  4. Kuiper JG, Sanchez RJ, Houben E et al. Use of Lipid-Modifying Therapy and LDL-C Goal Attainment in a High-Cardiovascular-Risk Population in the Netherlands. Clinical therapeutics 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28347514
  5. Leibowitz M, Cohen-Stavi C, Basu S, Balicer RD. Targeting LDL Cholesterol: Beyond Absolute Goals Toward Personalized Risk. Current cardiology reports 2017; 19:52. http://www.ncbi.nlm.nih.gov/pubmed/?term=28432662
  6. Jellinger PS, Handelsman Y, Rosenblit PD et al. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2017; 23:1-87. http://www.ncbi.nlm.nih.gov/pubmed/?term=28437620
  7. Mortensen MB, Nordestgaard BG, Afzal S, Falk E. ACC/AHA guidelines superior to ESC/EAS guidelines for primary prevention with statins in non-diabetic Europeans: the Copenhagen General Population Study. Eur Heart J 2017; 38:586-594. http://www.ncbi.nlm.nih.gov/pubmed/?term=28363217
  8. Eccleston D, Horrigan M, Rafter T et al. Improving Guideline Compliance in Australia With a National Percutaneous Coronary Intervention Outcomes Registry. Heart, lung & circulation 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28389196
  9. Atkins ER, Du X, Wu Y et al. Use of cardiovascular prevention treatments after acute coronary syndrome in China and associated factors. Int J Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28389125
  10. Miedema MD, Garberich RF, Schnaidt LJ et al. Statin Eligibility and Outpatient Care Prior to ST-Segment Elevation Myocardial Infarction. J Am Heart Assoc 2017; 6. http://www.ncbi.nlm.nih.gov/pubmed/?term=28404560
  11. Miedema MD, Sidebottom AC, Sillah A et al. Clinical implications of the American College of Cardiology/American Heart Association guidelines for the treatment of blood cholesterol for a rural community: Data from the Heart of New Ulm Project. J Clin Lipidol 2017; 11:94-101. http://www.ncbi.nlm.nih.gov/pubmed/?term=28391916
  12. Pagidipati NJ, Navar AM, Mulder H et al. Comparison of Recommended Eligibility for Primary Prevention Statin Therapy Based on the US Preventive Services Task Force Recommendations vs the ACC/AHA Guidelines. Jama 2017; 317:1563-1567. http://www.ncbi.nlm.nih.gov/pubmed/?term=28418481

LDL- related parameters

  1. Bagdade J, Barter P, Quiroga C, Alaupovic P. Effects of Torcetrapib and Statin Treatment on ApoC-III and Apoprotein-Defined Lipoprotein Subclasses (from the ILLUMINATE Trial). Am J Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28431663
  2. Butters J, Brown A, Griffith L et al. Clinical Outcomes in Trials Evaluating Lipid-Lowering Drugs. Am J Cardiovasc Drugs 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28432573
  3. Averna M, Stroes E. How to assess and manage cardiovascular risk associated with lipid alterations beyond LDL. Atherosclerosis. Supplements 2017; 26:16-24. http://www.ncbi.nlm.nih.gov/pubmed/?term=28434480
  4. Kaplon-Cieslicka A, Michalak M, Koltowski L, Filipiak KJ. How has the treatment of hypercholesterolemia in Poland changed over the last 6 years? Cardiology journal 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28394011
  5. Sniderman AD, Kiss RS, Reid T et al. Statins, PCSK9 inhibitors and cholesterol homeostasis: a view from within the hepatocyte. Clinical science (London, England : 1979) 2017; 131:791-797. http://www.ncbi.nlm.nih.gov/pubmed/?term=28424373
  6. Kuiper JG, Sanchez RJ, Houben E et al. Use of Lipid-Modifying Therapy and LDL-C Goal Attainment in a High-Cardiovascular-Risk Population in the Netherlands. Clinical therapeutics 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28347514
  7. Ference BA, Ginsberg HN, Graham I et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28444290
  8. Lafeber M, Spiering W, Visseren FL et al. Impact of switching from different treatment regimens to a fixed-dose combination pill (polypill) in patients with cardiovascular disease or similarly high risk. Eur J Prev Cardiol 2017:2047487317695616. http://www.ncbi.nlm.nih.gov/pubmed/?term=28436727
  9. Silbernagel G, Scharnagl H, Kleber ME et al. Circulating proprotein convertase subtilisin-kexin type 9, all-cause mortality, and cardiovascular mortality: The Ludwigshafen Risk and Cardiovascular Health study. Eur J Prev Cardiol 2017:2047487317693938. http://www.ncbi.nlm.nih.gov/pubmed/?term=28436724
  10. Miedema MD, Garberich RF, Schnaidt LJ et al. Statin Eligibility and Outpatient Care Prior to ST-Segment Elevation Myocardial Infarction. J Am Heart Assoc 2017; 6. http://www.ncbi.nlm.nih.gov/pubmed/?term=28404560
  11. Miedema MD, Sidebottom AC, Sillah A et al. Clinical implications of the American College of Cardiology/American Heart Association guidelines for the treatment of blood cholesterol for a rural community: Data from the Heart of New Ulm Project. J Clin Lipidol 2017; 11:94-101. http://www.ncbi.nlm.nih.gov/pubmed/?term=28391916
  12. Thongtang N, Diffenderfer MR, Ooi EM et al. Metabolism and proteomics of large and small dense LDL in combined hyperlipidemia. Effects of rosuvastatin. Journal of lipid research 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28392500
  13. Rafeeq MM, Habib HS, Murad H et al. Effect of rosuvastatin on dyslipidemia and other parameters associated with metabolic syndrome in Saudi patients. Nigerian journal of clinical practice 2017; 20:445-453. http://www.ncbi.nlm.nih.gov/pubmed/?term=28406125

Meta-analyses

  1. Liu B, Yi Z, Guan X et al. The relationship between statins and breast cancer prognosis varies by statin type and exposure time: a meta-analysis. Breast Cancer Res Treat 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28432513
  2. Yu EJ, Graber JM, Lu SE et al. Effect of Metformin and Statin Use on Survival in Pancreatic Cancer Patients: a Systematic Literature Review and Meta-analysis. Curr Med Chem 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28403788
  3. Kunutsor SK, Seidu S, Khunti K. Statins and secondary prevention of venous thromboembolism: pooled analysis of published observational cohort studies. Eur Heart J 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28369602
  4. He XX, Zhang R, Zuo PY et al. The efficacy advantage of evolocumab (AMG 145) dosed at 140mg every 2weeks versus 420mg every 4weeks in patients with hypercholesterolemia: Evidence from a meta-analysis. Eur J Intern Med 2017; 38:52-60. http://www.ncbi.nlm.nih.gov/pubmed/?term=28341307
  5. Gui YJ, Liao CX, Liu Q et al. Efficacy and safety of statins and exercise combination therapy compared to statin monotherapy in patients with dyslipidaemia: A systematic review and meta-analysis. Eur J Prev Cardiol 2017:2047487317691874. http://www.ncbi.nlm.nih.gov/pubmed/?term=28436720
  6. Casula M, Mozzanica F, Scotti L et al. Statin use and risk of new-onset diabetes: A meta-analysis of observational studies. Nutrition, metabolism, and cardiovascular diseases : NMCD 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28416099
  7. Catapano AL, Lee LV, Louie MJ et al. Efficacy of alirocumab according to background statin type and dose: pooled analysis of 8 ODYSSEY Phase 3 clinical trials. Scientific reports 2017; 7:45788. http://www.ncbi.nlm.nih.gov/pubmed/?term=28374849

Metabolic Syndrome - Diabetes

  1. Policardo L, Seghieri G, Anichini R, Francesconi P. Effect of statins on hospitalization risk of bacterial infections in patients with or without diabetes. Acta diabetologica 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28421335
  2. Cariou B, Leiter LA, Muller-Wieland D et al. Efficacy and safety of alirocumab in insulin-treated patients with type 1 or type 2 diabetes and high cardiovascular risk: Rationale and design of the ODYSSEY DM-INSULIN trial. Diabetes Metab 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28347654
  3. Lunder M, Janic M, Savic V et al. Very low-dose fluvastatin-valsartan combination decreases parameters of inflammation and oxidative stress in patients with type 1 diabetes mellitus. Diabetes Res Clin Pract 2017; 127:181-186. http://www.ncbi.nlm.nih.gov/pubmed/?term=28384560
  4. Parida S, Swain TR, Routray SN, Maiti R. Effect of Atorvastatin on Glycaemic Parameters in Normoglycaemic and Prediabetic Subjects: A Prospective, Panel Study. J Clin Diagn Res 2017; 11:Fc04-fc09. http://www.ncbi.nlm.nih.gov/pubmed/?term=28384881
  5. Hsu CY, Chen YT, Su YW et al. Statin therapy reduces future risk of lower limb amputation in patient with diabetes and peripheral artery disease. J Clin Endocrinol Metab 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28398564
  6. Hackett G, Jones PW, Strange RC, Ramachandran S. Statin, testosterone and phosphodiesterase 5-inhibitor treatments and age related mortality in diabetes. World J Diabetes 2017; 8:104-111. http://www.ncbi.nlm.nih.gov/pubmed/?term=28344753

New Treatments

  1. Arai H, Yamashita S, Yokote K et al. Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated receptor alpha modulator (SPPARMalpha), in combination with statin treatment: Two randomised, double-blind, placebo-controlled clinical trials in patients with dyslipidaemia. Atherosclerosis 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28410749
  2. Nicholls SJ, Ray KK, Ballantyne CM et al. Comparative effects of cholesteryl ester transfer protein inhibition, statin or ezetimibe on lipid factors: The ACCENTUATE trial. Atherosclerosis 2017; 261:12-18. http://www.ncbi.nlm.nih.gov/pubmed/?term=28412650
  3. Di Bartolo B, Scherer DJ, Brown A et al. PCSK9 Inhibitors in Hyperlipidemia: Current Status and Clinical Outlook. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28424973
  4. Hirayama A, Yamashita S, Inomata H et al. One-Year Efficacy and Safety of Evolocumab in Japanese Patients- A Pooled Analysis From the Open-Label Extension OSLER Studies. Circulation journal : official journal of the Japanese Circulation Society 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28367845
  5. Knowles JW, Howard WB, Karayan L et al. Access to Non-Statin Lipid Lowering Therapies in Patients at High-Risk of Atherosclerotic Cardiovascular Disease. Circulation 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28446516
  6. Sniderman AD, Kiss RS, Reid T et al. Statins, PCSK9 inhibitors and cholesterol homeostasis: a view from within the hepatocyte. Clinical science (London, England : 1979) 2017; 131:791-797. http://www.ncbi.nlm.nih.gov/pubmed/?term=28424373
  7. Villa G, Lothgren M, Kutikova L et al. Cost-Effectiveness of Evolocumab in Patients With High Cardiovascular Risk in Spain. Clinical therapeutics 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28366593
  8. He XX, Zhang R, Zuo PY et al. The efficacy advantage of evolocumab (AMG 145) dosed at 140mg every 2weeks versus 420mg every 4weeks in patients with hypercholesterolemia: Evidence from a meta-analysis. Eur J Intern Med 2017; 38:52-60. http://www.ncbi.nlm.nih.gov/pubmed/?term=28341307
  9. Zhang PY. PCSK9 as a therapeutic target for cardiovascular disease. Experimental and therapeutic medicine 2017; 13:810-814. http://www.ncbi.nlm.nih.gov/pubmed/?term=28450903
  10. Della Pepa G, Bozzetto L, Annuzzi G, Rivellese AA. Alirocumab for the treatment of hypercholesterolaemia. Expert Rev Clin Pharmacol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28395555
  11. Sultan Alvi S, Ansari IA, Khan I et al. Potential role of lycopene in targeting proprotein convertase subtilisin/kexin type-9 to combat hypercholesterolemia. Free radical biology & medicine 2017; 108:394-403. http://www.ncbi.nlm.nih.gov/pubmed/?term=28412198
  12. Scherer DJ, Nelson A, Psaltis PJ, Nicholls SJ. Targeting LDL Cholesterol with PCSK9 Inhibitors. Internal medicine journal 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28401639
  13. Kastelein JJ, Hovingh GK, Langslet G et al. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial hypercholesterolemia. J Clin Lipidol 2017; 11:195-203.e194. http://www.ncbi.nlm.nih.gov/pubmed/?term=28391886
  14. Momtazi AA, Banach M, Pirro M et al. Regulation of PCSK9 by nutraceuticals. Pharmacol Res 2017; 120:157-169. http://www.ncbi.nlm.nih.gov/pubmed/?term=28363723
  15. Catapano AL, Lee LV, Louie MJ et al. Efficacy of alirocumab according to background statin type and dose: pooled analysis of 8 ODYSSEY Phase 3 clinical trials. Scientific reports 2017; 7:45788. http://www.ncbi.nlm.nih.gov/pubmed/?term=28374849

PAD and statins

  1. Hsu CY, Chen YT, Su YW et al. Statin therapy reduces future risk of lower limb amputation in patient with diabetes and peripheral artery disease. J Clin Endocrinol Metab 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28398564
  2. DeCarlo C, Scher L, Shariff S et al. Statin use and other factors associated with mortality after major lower extremity amputation. Journal of vascular surgery 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28431865

Pleiotropic effects of statins

  1. Policardo L, Seghieri G, Anichini R, Francesconi P. Effect of statins on hospitalization risk of bacterial infections in patients with or without diabetes. Acta diabetologica 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28421335
  2. Safouris A, Krogias C, Sharma VK et al. Statin Pretreatment and Microembolic Signals in Large Artery Atherosclerosis. Arterioscler Thromb Vasc Biol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28450295
  3. Mansour H, Ghaleb R. Atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery. Atherosclerosis. Supplements 2017; 25:e2. http://www.ncbi.nlm.nih.gov/pubmed/?term=28452305
  4. Kanate AS, Hari PN, Pasquini MC et al. Recipient Immune-Modulation with Atorvastatin for Acute Graft-Versus-Host Disease Prophylaxis Following Allogeneic Transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28412518
  5. Zhao G, Wu L, Liu Y et al. Rosuvastatin reduces the recurrence rate following catheter ablation for atrial fibrillation in patients with heart failure. Biomedical reports 2017; 6:346-352. http://www.ncbi.nlm.nih.gov/pubmed/?term=28451398
  6. Yu Y, Zhu C, Liu C, Gao Y. Effect of Prior Atorvastatin Treatment on the Frequency of Hospital Acquired Pneumonia and Evolution of Biomarkers in Patients with Acute Ischemic Stroke: A Multicenter Prospective Study. BioMed research international 2017; 2017:5642704. http://www.ncbi.nlm.nih.gov/pubmed/?term=28357403
  7. Wiggers JK, van Golen RF, Verheij J et al. Atorvastatin does not protect against ischemia-reperfusion damage in cholestatic rat livers. BMC surgery 2017; 17:35. http://www.ncbi.nlm.nih.gov/pubmed/?term=28399849
  8. Hoppe C, Jacob E, Styles L et al. Simvastatin reduces vaso-occlusive pain in sickle cell anaemia: a pilot efficacy trial. British journal of haematology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28369718
  9. Taghizadeh M, Noruzinia M. Lovastatin Reduces Stemness via Epigenetic Reprograming of BMP2 and GATA2 in Human Endometrium and Endometriosis. Cell journal 2017; 19:50-64. http://www.ncbi.nlm.nih.gov/pubmed/?term=28367417
  10. Kunutsor SK, Seidu S, Khunti K. Statins and secondary prevention of venous thromboembolism: pooled analysis of published observational cohort studies. Eur Heart J 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28369602
  11. Tian FM, Li SY, Yang K et al. Orally administered simvastatin partially preserves lumbar vertebral bone mass but not integrity of intervertebral discs in ovariectomized rats. Experimental and therapeutic medicine 2017; 13:877-884. http://www.ncbi.nlm.nih.gov/pubmed/?term=28450913
  12. Zhu B, Gong Y, Yan G et al. Atorvastatin treatment modulates p16 promoter methylation to regulate p16 expression. The FEBS journal 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28425161
  13. Zijah V, Salehi R, Aghazadeh M et al. Towards optimization of odonto/osteogenic bioengineering: in vitro comparison of simvastatin, sodium fluoride, melanocyte-stimulating hormone. In vitro cellular & developmental biology. Animal 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28342024
  14. Ribeiro NQ, Costa MC, Magalhaes TFF et al. Atorvastatin as a promising anticryptococcal agent. International journal of antimicrobial agents 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28450174
  15. Frohlich H, Raman N, Tager T et al. Statins attenuate but do not eliminate the reverse epidemiology of total serum cholesterol in patients with non-ischemic chronic heart failure. Int J Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28342630
  16. Santos BF, Souza EQ, Brigagao MR et al. Local application of statins in the treatment of experimental periodontal disease in rats. Journal of applied oral science : revista FOB 2017; 25:168-176. http://www.ncbi.nlm.nih.gov/pubmed/?term=28403357
  17. Guo Q, Liu C, Hai B et al. Chitosan conduits filled with simvastatin/Pluronic F-127 hydrogel promote peripheral nerve regeneration in rats. Journal of biomedical materials research. Part B, Applied biomaterials 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28371231
  18. S SM, Kumari M, Pradeep AR et al. Comparative evaluation of efficacy of subgingivally delivered 1.2% Atorvastatin and 1.2% Simvastatin in the treatment of intrabony defects in chronic periodontitis: a randomized controlled trial. Journal of dental research, dental clinics, dental prospects 2017; 11:18-25. http://www.ncbi.nlm.nih.gov/pubmed/?term=28413591
  19. Feng Y, Lei B, Zhang F et al. Anti-inflammatory effects of simvastatin during the resolution phase of experimentally formed venous thrombi. Journal of investigative medicine : the official publication of the American Federation for Clinical Research 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28442532
  20. Mirjanic-Azaric B, Jelic-Ivanovic Z, Zeljkovic A et al. The Pleiotropic Effects of Atorvastatin on Stable Angina Patients: Evidence by Analysis of High-Density Lipoprotein Size and Subclasses, and Plasma mRNA. Journal of medical biochemistry 2015; 34:314-322. http://www.ncbi.nlm.nih.gov/pubmed/?term=28356842
  21. Lee WS, Lee EG, Sung MS et al. Atorvastatin inhibits osteoclast differentiation by suppressing NF-kappaB and MAPK signaling during IL-1beta-induced osteoclastogenesis. The Korean journal of internal medicine 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28352062
  22. Huang Z, Zhang L, Feng X et al. A new in vivo method to retard progression of intervertebral disc degeneration through stimulation of endogenous stem cells with simvastatin. Medical hypotheses 2017; 101:65-66. http://www.ncbi.nlm.nih.gov/pubmed/?term=28351496
  23. Rea F, Bonassi S, Vitale C et al. Exposure to statins is associated to fracture risk reduction in elderly people with cardiovascular disease: evidence from the AIFA-I-GrADE observational project. Pharmacoepidemiol Drug Saf 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28370905
  24. Li Y, Lu G, Sun D et al. Inhibition of endoplasmic reticulum stress signaling pathway: A new mechanism of statins to suppress the development of abdominal aortic aneurysm. PLoS One 2017; 12:e0174821. http://www.ncbi.nlm.nih.gov/pubmed/?term=28369137
  25. Rozani V, Giladi N, El-Ad B et al. Statin adherence and the risk of Parkinson's disease: A population-based cohort study. PLoS One 2017; 12:e0175054. http://www.ncbi.nlm.nih.gov/pubmed/?term=28388626

Primary Prevention

  1. de Lemos JA, Ayers CR, Levine BD et al. A Multimodality Strategy for Cardiovascular Risk Assessment: Performance in Two Population-Based Cohorts. Circulation 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28360032
  2. Ridker PM, Lonn E, Paynter NP et al. Primary Prevention With Statin Therapy in the Elderly: New Meta-Analyses from the Contemporary JUPITER and HOPE-3 Randomized Trials. Circulation 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28385949
  3. Thompson A, Guthrie B, Payne K. Using the Payoff Time in Decision-Analytic Models: A Case Study for Using Statins in Primary Prevention. Med Decis Making 2017:272989x17700846. http://www.ncbi.nlm.nih.gov/pubmed/?term=28441087

Registry data

  1. Policardo L, Seghieri G, Anichini R, Francesconi P. Effect of statins on hospitalization risk of bacterial infections in patients with or without diabetes. Acta diabetologica 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28421335
  2. Alsabbagh MW, Eurich D, Lix LM et al. Does the association between adherence to statin medications and mortality depend on measurement approach? A retrospective cohort study. BMC medical research methodology 2017; 17:66. http://www.ncbi.nlm.nih.gov/pubmed/?term=28427340
  3. Svendsen TK, Hansen PN, Garcia Rodriguez LA et al. Statins and polyneuropathy revisited: Case-control study in Denmark, 1999-2013. Br J Clin Pharmacol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28370351
  4. Naugler C, Cook C, Morrin L et al. Statin Prescriptions for High-Risk Patients Are Increased by Laboratory-Initiated Framingham Risk Scores: A Quality-Improvement Initiative. Can J Cardiol 2017; 33:682-684. http://www.ncbi.nlm.nih.gov/pubmed/?term=28449839
  5. Reda A, Etman A, Abdel-Rahim A et al. Centralized Pan-Middle East Survey on the Under-Treatment of Hypercholesterolemia: Results from the CEPHEUS II Study in Egypt. Cardiology and therapy 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28357773
  6. Taghizadeh M, Noruzinia M. Lovastatin Reduces Stemness via Epigenetic Reprograming of BMP2 and GATA2 in Human Endometrium and Endometriosis. Cell journal 2017; 19:50-64. http://www.ncbi.nlm.nih.gov/pubmed/?term=28367417
  7. Manns L, Scott-Douglas N, Tonelli M et al. A Population-Based Analysis of Quality Indicators in CKD. Clin J Am Soc Nephrol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28377473
  8. Kuiper JG, Sanchez RJ, Houben E et al. Use of Lipid-Modifying Therapy and LDL-C Goal Attainment in a High-Cardiovascular-Risk Population in the Netherlands. Clinical therapeutics 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28347514
  9. Malo S, Aguilar-Palacio I, Feja C et al. Different approaches to the assessment of adherence and persistence with cardiovascular-disease preventive medications. Current medical research and opinion 2017:1-18. http://www.ncbi.nlm.nih.gov/pubmed/?term=28422521
  10. Balder JW, de Vries JK, Mulder DJ, Kamphuisen PW. Time to improve statin prescription guidelines in low-risk patients? Eur J Prev Cardiol 2017:2047487317698585. http://www.ncbi.nlm.nih.gov/pubmed/?term=28429651
  11. Silbernagel G, Scharnagl H, Kleber ME et al. Circulating proprotein convertase subtilisin-kexin type 9, all-cause mortality, and cardiovascular mortality: The Ludwigshafen Risk and Cardiovascular Health study. Eur J Prev Cardiol 2017:2047487317693938. http://www.ncbi.nlm.nih.gov/pubmed/?term=28436724
  12. Lum CJ, Nakagawa K, Shohet RV et al. The Cost-Benefit Balance of Statins in Hawai'i: A Moving Target. Hawai'i journal of medicine & public health : a journal of Asia Pacific Medicine & Public Health 2017; 76:99-102. http://www.ncbi.nlm.nih.gov/pubmed/?term=28428922
  13. Eccleston D, Horrigan M, Rafter T et al. Improving Guideline Compliance in Australia With a National Percutaneous Coronary Intervention Outcomes Registry. Heart, lung & circulation 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28389196
  14. Epstein MM, Divine G, Chao CR et al. Statin use and risk of multiple myeloma: An analysis from the Cancer Research Network. International journal of cancer. Journal international du cancer 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28425616
  15. Verdoodt F, Kjaer Hansen M, Kjaer SK et al. Statin use and mortality among ovarian cancer patients: A population-based cohort study. International journal of cancer. Journal international du cancer 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28411390
  16. Atkins ER, Du X, Wu Y et al. Use of cardiovascular prevention treatments after acute coronary syndrome in China and associated factors. Int J Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28389125
  17. Bonsu KO, Owusu IK, Buabeng KO et al. Statin Treatment and Clinical Outcomes of Heart Failure Among Africans: An Inverse Probability Treatment Weighted Analysis. J Am Heart Assoc 2017; 6. http://www.ncbi.nlm.nih.gov/pubmed/?term=28365564
  18. Miedema MD, Garberich RF, Schnaidt LJ et al. Statin Eligibility and Outpatient Care Prior to ST-Segment Elevation Myocardial Infarction. J Am Heart Assoc 2017; 6. http://www.ncbi.nlm.nih.gov/pubmed/?term=28404560
  19. Hsu CY, Chen YT, Su YW et al. Statin therapy reduces future risk of lower limb amputation in patient with diabetes and peripheral artery disease. J Clin Endocrinol Metab 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28398564
  20. Pearlman M, Covin Y, Schmidt R et al. Statins and Lower Gastrointestinal Conditions: A Retrospective Cohort Study. Journal of clinical pharmacology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28398604
  21. Krumme AA, Franklin JM, Isaman DL et al. Predicting 1-Year Statin Adherence Among Prevalent Users: A Retrospective Cohort Study. Journal of managed care & specialty pharmacy 2017; 23:494-502. http://www.ncbi.nlm.nih.gov/pubmed/?term=28345442
  22. DeCarlo C, Scher L, Shariff S et al. Statin use and other factors associated with mortality after major lower extremity amputation. Journal of vascular surgery 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28431865
  23. Colantonio LD, Huang L, Monda KL et al. Adherence to High-Intensity Statins Following a Myocardial Infarction Hospitalization Among Medicare Beneficiaries. JAMA cardiology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28423147
  24. Albright KC, Zhao H, Blackburn J et al. Racial differences in statin adherence following hospital discharge for ischemic stroke. Neurology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28404800
  25. Gavronski M, Volmer D, Hartikainen S, Zharkovsky A. Potential drug interactions with statins: Estonian register-based study. Open medicine (Warsaw, Poland) 2015; 10:254-260. http://www.ncbi.nlm.nih.gov/pubmed/?term=28352703
  26. Rea F, Bonassi S, Vitale C et al. Exposure to statins is associated to fracture risk reduction in elderly people with cardiovascular disease: evidence from the AIFA-I-GrADE observational project. Pharmacoepidemiol Drug Saf 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28370905
  27. Rozani V, Giladi N, El-Ad B et al. Statin adherence and the risk of Parkinson's disease: A population-based cohort study. PLoS One 2017; 12:e0175054. http://www.ncbi.nlm.nih.gov/pubmed/?term=28388626
  28. Zhao M, Klipstein-Grobusch K, Wang X et al. Prevalence of cardiovascular medication on secondary prevention after myocardial infarction in China between 1995-2015: A systematic review and meta-analysis. PLoS One 2017; 12:e0175947. http://www.ncbi.nlm.nih.gov/pubmed/?term=28426793
  29. Rockberg J, Jorgensen L, Taylor B et al. Risk of mortality and recurrent cardiovascular events in patients with acute coronary syndromes on high intensity statin treatment. Preventive medicine reports 2017; 6:203-209. http://www.ncbi.nlm.nih.gov/pubmed/?term=28373930

Renal Disease

  1. Manns L, Scott-Douglas N, Tonelli M et al. A Population-Based Analysis of Quality Indicators in CKD. Clin J Am Soc Nephrol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28377473
  2. Sana T, Aslam B, Aslam N et al. Therapeutic effect of atorvastatin on kidney functions and urinary excretion of Glimepiride in healthy adult human male subjects. Pak J Pharm Sci 2016; 29:2321-2326. http://www.ncbi.nlm.nih.gov/pubmed/?term=28375090

Reviews

  1. Policardo L, Seghieri G, Anichini R, Francesconi P. Effect of statins on hospitalization risk of bacterial infections in patients with or without diabetes. Acta diabetologica 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28421335
  2. Butters J, Brown A, Griffith L et al. Clinical Outcomes in Trials Evaluating Lipid-Lowering Drugs. Am J Cardiovasc Drugs 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28432573
  3. Averna M, Stroes E. How to assess and manage cardiovascular risk associated with lipid alterations beyond LDL. Atherosclerosis. Supplements 2017; 26:16-24. http://www.ncbi.nlm.nih.gov/pubmed/?term=28434480
  4. Laufs U, Filipiak KJ, Gouni-Berthold I, Catapano AL. Practical aspects in the management of statin-associated muscle symptoms (SAMS). Atherosclerosis. Supplements 2017; 26:45-55. http://www.ncbi.nlm.nih.gov/pubmed/?term=28434484
  5. Di Bartolo B, Scherer DJ, Brown A et al. PCSK9 Inhibitors in Hyperlipidemia: Current Status and Clinical Outlook. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28424973
  6. Kaplon-Cieslicka A, Michalak M, Koltowski L, Filipiak KJ. How has the treatment of hypercholesterolemia in Poland changed over the last 6 years? Cardiology journal 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28394011
  7. Hausner H, Derving Karsbol J, Holst AG et al. Effect of Semaglutide on the Pharmacokinetics of Metformin, Warfarin, Atorvastatin and Digoxin in Healthy Subjects. Clinical pharmacokinetics 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28349387
  8. Sniderman AD, Kiss RS, Reid T et al. Statins, PCSK9 inhibitors and cholesterol homeostasis: a view from within the hepatocyte. Clinical science (London, England : 1979) 2017; 131:791-797. http://www.ncbi.nlm.nih.gov/pubmed/?term=28424373
  9. Leibowitz M, Cohen-Stavi C, Basu S, Balicer RD. Targeting LDL Cholesterol: Beyond Absolute Goals Toward Personalized Risk. Current cardiology reports 2017; 19:52. http://www.ncbi.nlm.nih.gov/pubmed/?term=28432662
  10. Md KF, Grunfeld C. Triglyceride Lowering Drugs. In: Endotext. Edited by: De Groot LJ, Chrousos G, Dungan K et al. South Dartmouth (MA): MDText.com, Inc.; 2000.
  11. Ference BA, Ginsberg HN, Graham I et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28444290
  12. Nilsson J. Atherosclerotic plaque vulnerability in the statin era. Eur Heart J 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28387815
  13. Zhang PY. PCSK9 as a therapeutic target for cardiovascular disease. Experimental and therapeutic medicine 2017; 13:810-814. http://www.ncbi.nlm.nih.gov/pubmed/?term=28450903
  14. Della Pepa G, Bozzetto L, Annuzzi G, Rivellese AA. Alirocumab for the treatment of hypercholesterolaemia. Expert Rev Clin Pharmacol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28395555
  15. Scherer DJ, Nelson A, Psaltis PJ, Nicholls SJ. Targeting LDL Cholesterol with PCSK9 Inhibitors. Internal medicine journal 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28401639
  16. Backes JM, Ruisinger JF, Gibson CA, Moriarty PM. Statin-associated muscle symptoms-Managing the highly intolerant. J Clin Lipidol 2017; 11:24-33. http://www.ncbi.nlm.nih.gov/pubmed/?term=28391891
  17. Poinsot P, Collardeau Frachon S, Restier L et al. Childhood/adult-onset lysosomal acid lipase deficiency: A serious metabolic and vascular phenotype beyond liver disease-four new pediatric cases. J Clin Lipidol 2017; 11:167-177.e163. http://www.ncbi.nlm.nih.gov/pubmed/?term=28391883
  18. Kovacevic SV, Miljkovic B, Culafic M et al. Evaluation of drug-related problems in older polypharmacy primary care patients. J Eval Clin Pract 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28370742
  19. Pagidipati NJ, Navar AM, Mulder H et al. Comparison of Recommended Eligibility for Primary Prevention Statin Therapy Based on the US Preventive Services Task Force Recommendations vs the ACC/AHA Guidelines. Jama 2017; 317:1563-1567. http://www.ncbi.nlm.nih.gov/pubmed/?term=28418481
  20. Tarr PE, Kovari H. Another statin option in HIV. The lancet. HIV 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28416196
  21. Momtazi AA, Banach M, Pirro M et al. Regulation of PCSK9 by nutraceuticals. Pharmacol Res 2017; 120:157-169. http://www.ncbi.nlm.nih.gov/pubmed/?term=28363723

Safety and side effects

  1. Wiggins BS, Lamprecht DG, Jr., Page RL, 2nd, Saseen JJ. Recommendations for Managing Drug-Drug Interactions with Statins and HIV Medications. Am J Cardiovasc Drugs 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28364370
  2. Laufs U, Filipiak KJ, Gouni-Berthold I, Catapano AL. Practical aspects in the management of statin-associated muscle symptoms (SAMS). Atherosclerosis. Supplements 2017; 26:45-55. http://www.ncbi.nlm.nih.gov/pubmed/?term=28434484
  3. Svendsen TK, Hansen PN, Garcia Rodriguez LA et al. Statins and polyneuropathy revisited: Case-control study in Denmark, 1999-2013. Br J Clin Pharmacol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28370351
  4. Brennan ET, Joy TR. Management Strategies for Statin-Associated Muscle Symptoms: How Useful Is Same-Statin Rechallenge? Can J Cardiol 2017; 33:666-673. http://www.ncbi.nlm.nih.gov/pubmed/?term=28449837
  5. de la Pena A, Cui X, Geiser J, Loghin C. No Dose Adjustment is Recommended for Digoxin, Warfarin, Atorvastatin or a Combination Oral Contraceptive When Coadministered with Dulaglutide. Clinical pharmacokinetics 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28357715
  6. Pasha R, Moon TW. Coenzyme Q10 protects against statin-induced myotoxicity in zebrafish larvae (Danio rerio). Environmental toxicology and pharmacology 2017; 52:150-160. http://www.ncbi.nlm.nih.gov/pubmed/?term=28414942
  7. Busanello ENB, Marques AC, Lander N et al. Pravastatin Chronic Treatment Sensitizes Hypercholesterolemic Mice Muscle to Mitochondrial Permeability Transition: Protection by Creatine or Coenzyme Q10. Frontiers in pharmacology 2017; 8:185. http://www.ncbi.nlm.nih.gov/pubmed/?term=28424622
  8. Parida S, Swain TR, Routray SN, Maiti R. Effect of Atorvastatin on Glycaemic Parameters in Normoglycaemic and Prediabetic Subjects: A Prospective, Panel Study. J Clin Diagn Res 2017; 11:Fc04-fc09. http://www.ncbi.nlm.nih.gov/pubmed/?term=28384881
  9. Choudhary NS, Saigal S, Saraf N, Soin AS. Acute Onset Significant Muscle Weakness in a Patient Awaiting Liver Transplantation: Look for Statins. J Clin Exp Hepatol 2017; 7:66-67. http://www.ncbi.nlm.nih.gov/pubmed/?term=28348473
  10. Backes JM, Ruisinger JF, Gibson CA, Moriarty PM. Statin-associated muscle symptoms-Managing the highly intolerant. J Clin Lipidol 2017; 11:24-33. http://www.ncbi.nlm.nih.gov/pubmed/?term=28391891
  11. Graham JH, Sanchez RJ, Saseen JJ et al. Clinical and economic consequences of statin intolerance in the United States: Results from an integrated health system. J Clin Lipidol 2017; 11:70-79.e71. http://www.ncbi.nlm.nih.gov/pubmed/?term=28391913
  12. Pearlman M, Covin Y, Schmidt R et al. Statins and Lower Gastrointestinal Conditions: A Retrospective Cohort Study. Journal of clinical pharmacology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28398604
  13. Kovacevic SV, Miljkovic B, Culafic M et al. Evaluation of drug-related problems in older polypharmacy primary care patients. J Eval Clin Pract 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28370742
  14. Yu L, Da XW, Wu XL et al. Simvastatin prevents lipopolysaccharide-induced septic shock in rats. Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban 2017; 37:226-230. http://www.ncbi.nlm.nih.gov/pubmed/?term=28397043
  15. Oda T, Sawada Y, Yamaguchi T et al. Drug Eruption Caused by Rosuvastatin. J Investig Allergol Clin Immunol 2017; 27:140-141. http://www.ncbi.nlm.nih.gov/pubmed/?term=28398205
  16. Johnson PK, Mendelson MM, Baker A et al. Statin-Associated Myopathy in a Pediatric Preventive Cardiology Practice. J Pediatr 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28365026
  17. Saito S, Nakanishi T, Shirasaki Y et al. Association of miR-145 with statin-induced skeletal muscle toxicity in human rhabdomyosarcoma RD cells. Journal of pharmaceutical sciences 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28438533
  18. Wu HF, Hristeva N, Chang J et al. Rosuvastatin Pharmacokinetics in Asian and White Subjects wild-type for Both OATP1B1 and BCRP Under Control and Inhibited Conditions. Journal of pharmaceutical sciences 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28385543
  19. Casula M, Mozzanica F, Scotti L et al. Statin use and risk of new-onset diabetes: A meta-analysis of observational studies. Nutrition, metabolism, and cardiovascular diseases : NMCD 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28416099
  20. Gavronski M, Volmer D, Hartikainen S, Zharkovsky A. Potential drug interactions with statins: Estonian register-based study. Open medicine (Warsaw, Poland) 2015; 10:254-260. http://www.ncbi.nlm.nih.gov/pubmed/?term=28352703
  21. Jiang F, Choi JY, Lee JH et al. The influences of SLCO1B1 and ABCB1 genotypes on the pharmacokinetics of simvastatin, in relation to CYP3A4 inhibition. Pharmacogenomics 2017; 18:459-469. http://www.ncbi.nlm.nih.gov/pubmed/?term=28350522

Stroke and CNS

  1. Yu Y, Zhu C, Liu C, Gao Y. Effect of Prior Atorvastatin Treatment on the Frequency of Hospital Acquired Pneumonia and Evolution of Biomarkers in Patients with Acute Ischemic Stroke: A Multicenter Prospective Study. BioMed research international 2017; 2017:5642704. http://www.ncbi.nlm.nih.gov/pubmed/?term=28357403
  2. Al-Asmari AK, Ullah Z, Al Masoudi AS, Ahmad I. Simultaneous administration of fluoxetine and simvastatin ameliorates lipid profile, improves brain level of neurotransmitters, and increases bioavailability of simvastatin. Journal of experimental pharmacology 2017; 9:47-57. http://www.ncbi.nlm.nih.gov/pubmed/?term=28442937
  3. Shean KE, McCallum JC, Soden PA et al. Regional variation in patient selection and treatment for carotid artery disease in the Vascular Quality Initiative. Journal of vascular surgery 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28359719
  4. Liu G, Sterling NW, Kong L et al. Statins may facilitate Parkinson's disease: Insight gained from a large, national claims database. Movement disorders : official journal of the Movement Disorder Society 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28370314
  5. Albright KC, Zhao H, Blackburn J et al. Racial differences in statin adherence following hospital discharge for ischemic stroke. Neurology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28404800
  6. Elevated Baseline C-Reactive Protein as a Predictor of Outcome After Aneurysmal Subarachnoid Hemorrhage: Data From the Simvastatin in Aneurysmal Subarachnoid Hemorrhage (STASH) Trial: Erratum. Neurosurgery 2016; 79:945. http://www.ncbi.nlm.nih.gov/pubmed/?term=28426854
  7. Mott M, Koroshetz W, Wright CB. CREST-2: Identifying the Best Method of Stroke Prevention for Carotid Artery Stenosis: National Institute of Neurological Disorders and Stroke Organizational Update. Stroke 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28386040

Triglycerides/HDL

  1. Ridker PM, Lonn E, Paynter NP et al. Primary Prevention With Statin Therapy in the Elderly: New Meta-Analyses from the Contemporary JUPITER and HOPE-3 Randomized Trials. Circulation 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28385949
  2. Galway S, Adatia F, Grubisic M et al. Sex Differences in Cardiac Medication Use Post-Catheterization in Patients Undergoing Coronary Angiography for Stable Angina with Nonobstructive Coronary Artery Disease. Journal of women's health (2002) 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28384013
  3. Rea F, Bonassi S, Vitale C et al. Exposure to statins is associated to fracture risk reduction in elderly people with cardiovascular disease: evidence from the AIFA-I-GrADE observational project. Pharmacoepidemiol Drug Saf 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28370905

Trials

  1. Huded CP, Benck LR, Stone NJ et al. Relation of Intensity of Statin Therapy and Outcomes After Transcatheter Aortic Valve Replacement. Am J Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28395888
  2. Tan Q, Zhang S, Zou X et al. Fluvastatin therapy could not decrease progression of paroxysmal atrial fibrillation in non-valvular disease patients. Anatol J Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28430117
  3. Arai H, Yamashita S, Yokote K et al. Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated receptor alpha modulator (SPPARMalpha), in combination with statin treatment: Two randomised, double-blind, placebo-controlled clinical trials in patients with dyslipidaemia. Atherosclerosis 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28410749
  4. Nicholls SJ, Ray KK, Ballantyne CM et al. Comparative effects of cholesteryl ester transfer protein inhibition, statin or ezetimibe on lipid factors: The ACCENTUATE trial. Atherosclerosis 2017; 261:12-18. http://www.ncbi.nlm.nih.gov/pubmed/?term=28412650
  5. Kanate AS, Hari PN, Pasquini MC et al. Recipient Immune-Modulation with Atorvastatin for Acute Graft-Versus-Host Disease Prophylaxis Following Allogeneic Transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28412518
  6. Zhao G, Wu L, Liu Y et al. Rosuvastatin reduces the recurrence rate following catheter ablation for atrial fibrillation in patients with heart failure. Biomedical reports 2017; 6:346-352. http://www.ncbi.nlm.nih.gov/pubmed/?term=28451398
  7. Xu Y, Wang Y, Zhi J et al. Impact of matrix metalloproteinase 9 rs3918242 genetic variant on lipid-lowering efficacy of simvastatin therapy in Chinese patients with coronary heart disease. BMC pharmacology & toxicology 2017; 18:28. http://www.ncbi.nlm.nih.gov/pubmed/?term=28390432
  8. Wiggers JK, van Golen RF, Verheij J et al. Atorvastatin does not protect against ischemia-reperfusion damage in cholestatic rat livers. BMC surgery 2017; 17:35. http://www.ncbi.nlm.nih.gov/pubmed/?term=28399849
  9. Hoppe C, Jacob E, Styles L et al. Simvastatin reduces vaso-occlusive pain in sickle cell anaemia: a pilot efficacy trial. British journal of haematology 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28369718
  10. Al Kindi M, Belanger AM, Sayegh K et al. Aortic Calcification Progression in Heterozygote Familial Hypercholesterolemia. Can J Cardiol 2017; 33:658-665. http://www.ncbi.nlm.nih.gov/pubmed/?term=28449836
  11. Brennan ET, Joy TR. Management Strategies for Statin-Associated Muscle Symptoms: How Useful Is Same-Statin Rechallenge? Can J Cardiol 2017; 33:666-673. http://www.ncbi.nlm.nih.gov/pubmed/?term=28449837
  12. Hirayama A, Yamashita S, Inomata H et al. One-Year Efficacy and Safety of Evolocumab in Japanese Patients- A Pooled Analysis From the Open-Label Extension OSLER Studies. Circulation journal : official journal of the Japanese Circulation Society 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28367845
  13. Khera AV, Demler O, Adelman SJ et al. Cholesterol Efflux Capacity, HDL Particle Number, and Incident Cardiovascular Events. An Analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin). Circulation 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28450350
  14. Godino C, Pavon AG, Mangieri A et al. Platelet reactivity in response to loading dose of atorvastatin or rosuvastatin in patients with stable coronary disease before percutaneous coronary intervention: The STATIPLAT randomized study. Clin Cardiol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28422300
  15. Cariou B, Leiter LA, Muller-Wieland D et al. Efficacy and safety of alirocumab in insulin-treated patients with type 1 or type 2 diabetes and high cardiovascular risk: Rationale and design of the ODYSSEY DM-INSULIN trial. Diabetes Metab 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28347654
  16. Lunder M, Janic M, Savic V et al. Very low-dose fluvastatin-valsartan combination decreases parameters of inflammation and oxidative stress in patients with type 1 diabetes mellitus. Diabetes Res Clin Pract 2017; 127:181-186. http://www.ncbi.nlm.nih.gov/pubmed/?term=28384560
  17. Woo HI, Kim SR, Huh W et al. Association of genetic variations with pharmacokinetics and lipid-lowering response to atorvastatin in healthy Korean subjects. Drug design, development and therapy 2017; 11:1135-1146. http://www.ncbi.nlm.nih.gov/pubmed/?term=28435225
  18. Hagiwara N, Kawada-Watanabe E, Koyanagi R et al. Low-density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ-PROPER study, a prospective, open-label, randomized trial. Eur Heart J 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28430910
  19. Lafeber M, Spiering W, Visseren FL et al. Impact of switching from different treatment regimens to a fixed-dose combination pill (polypill) in patients with cardiovascular disease or similarly high risk. Eur J Prev Cardiol 2017:2047487317695616. http://www.ncbi.nlm.nih.gov/pubmed/?term=28436727
  20. Guo R, Yang L, Mu L et al. Long-term statin use before primary percutaneous coronary intervention improves treatment outcomes of acute myocardial infarction. Experimental and therapeutic medicine 2017; 13:1578-1583. http://www.ncbi.nlm.nih.gov/pubmed/?term=28413512
  21. Kebapcilar AG, Ilhan TT, Dursunoglu D et al. Efficacy comparison of oral rosuvastatin versus oral progesterone and bevacizumab on regression of surgically endometriotic implants in rats. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 2017:1-5. http://www.ncbi.nlm.nih.gov/pubmed/?term=28452240
  22. Umemoto T, Yasu T, Arao K et al. Pravastatin improves postprandial endothelial dysfunction and hemorheological deterioration in patients with effort angina pectoris. Heart Vessels 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28396938
  23. Hersi A, Giannoccaro JP, Howarth A et al. Statin Induced Regression of Cardiomyopathy Trial: A Randomized, Placebo-controlled Double-blind Trial. Heart views : the official journal of the Gulf Heart Association 2016; 17:129-135. http://www.ncbi.nlm.nih.gov/pubmed/?term=28400935
  24. Shinnakasu A, Yamamoto K, Kurano M et al. The Combination Therapy of Fenofibrate and Ezetimibe Improved Lipid Profile and Vascular Function Compared with Statins in Patients with Type 2 Diabetes. J Atheroscler Thromb 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28450679
  25. Chee YR, Watson RW, McCarthy J et al. High dose statin prophylaxis in cardiopulmonary bypass related surgery: clinical utility. Journal of cardiothoracic surgery 2017; 12:20. http://www.ncbi.nlm.nih.gov/pubmed/?term=28359339
  26. Bos S, Phillips M, Watts GF et al. Novel protein biomarkers associated with coronary artery disease in statin-treated patients with familial hypercholesterolemia. J Clin Lipidol 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28434814
  27. Kastelein JJ, Hovingh GK, Langslet G et al. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial hypercholesterolemia. J Clin Lipidol 2017; 11:195-203.e194. http://www.ncbi.nlm.nih.gov/pubmed/?term=28391886
  28. Nixon DE, Bosch RJ, Chan ES et al. Effects of atorvastatin on biomarkers of immune activation, inflammation, and lipids in virologically suppressed, human immunodeficiency virus-1-infected individuals with low-density lipoprotein cholesterol <130 mg/dL (AIDS Clinical Trials Group Study A5275). J Clin Lipidol 2017; 11:61-69. http://www.ncbi.nlm.nih.gov/pubmed/?term=28391912
  29. Turner RM, Yin P, Hanson A et al. Investigating the prevalence, predictors, and prognosis of suboptimal statin use early after a non-ST elevation acute coronary syndrome. J Clin Lipidol 2017; 11:204-214. http://www.ncbi.nlm.nih.gov/pubmed/?term=28391887
  30. Mirjanic-Azaric B, Jelic-Ivanovic Z, Zeljkovic A et al. The Pleiotropic Effects of Atorvastatin on Stable Angina Patients: Evidence by Analysis of High-Density Lipoprotein Size and Subclasses, and Plasma mRNA. Journal of medical biochemistry 2015; 34:314-322. http://www.ncbi.nlm.nih.gov/pubmed/?term=28356842
  31. Aberg JA, Sponseller CA, Ward DJ et al. Pitavastatin versus pravastatin in adults with HIV-1 infection and dyslipidaemia (INTREPID): 12 week and 52 week results of a phase 4, multicentre, randomised, double-blind, superiority trial. The lancet. HIV 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28416195
  32. Bangalore S, Fayyad R, Laskey R et al. Body-Weight Fluctuations and Outcomes in Coronary Disease. N Engl J Med 2017; 376:1332-1340. http://www.ncbi.nlm.nih.gov/pubmed/?term=28379800
  33. Elevated Baseline C-Reactive Protein as a Predictor of Outcome After Aneurysmal Subarachnoid Hemorrhage: Data From the Simvastatin in Aneurysmal Subarachnoid Hemorrhage (STASH) Trial: Erratum. Neurosurgery 2016; 79:945. http://www.ncbi.nlm.nih.gov/pubmed/?term=28426854
  34. Rafeeq MM, Habib HS, Murad H et al. Effect of rosuvastatin on dyslipidemia and other parameters associated with metabolic syndrome in Saudi patients. Nigerian journal of clinical practice 2017; 20:445-453. http://www.ncbi.nlm.nih.gov/pubmed/?term=28406125
  35. Jiang F, Choi JY, Lee JH et al. The influences of SLCO1B1 and ABCB1 genotypes on the pharmacokinetics of simvastatin, in relation to CYP3A4 inhibition. Pharmacogenomics 2017; 18:459-469. http://www.ncbi.nlm.nih.gov/pubmed/?term=28350522
  36. Madonna R, Renna FV, Lanuti P et al. The acute impact of high-dose lipid-lowering treatment on endothelial progenitor cells in patients with coronary artery disease-The REMEDY-EPC early substudy. PLoS One 2017; 12:e0172800. http://www.ncbi.nlm.nih.gov/pubmed/?term=28394933

Women and elderly

  1. Ridker PM, Lonn E, Paynter NP et al. Primary Prevention With Statin Therapy in the Elderly: New Meta-Analyses from the Contemporary JUPITER and HOPE-3 Randomized Trials. Circulation 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28385949
  2. Galway S, Adatia F, Grubisic M et al. Sex Differences in Cardiac Medication Use Post-Catheterization in Patients Undergoing Coronary Angiography for Stable Angina with Nonobstructive Coronary Artery Disease. Journal of women's health (2002) 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28384013
  3. Rea F, Bonassi S, Vitale C et al. Exposure to statins is associated to fracture risk reduction in elderly people with cardiovascular disease: evidence from the AIFA-I-GrADE observational project. Pharmacoepidemiol Drug Saf 2017. http://www.ncbi.nlm.nih.gov/pubmed/?term=28370905

Twitter
IAS Website
For information
You are now on the editors mailing list of the IAS Statin Newsletter.
The IAS Statin Newsletter is part of the IAS News and Literature update service.
 
This activity is supported by an educational grant from Pfizer.

Cancella iscrizione | Unsubscribe | Inviato con MailUp